*times shown in EST

8:30 am
Registration & Coffee

9:15 am Chair’s Opening Remarks

Consolidating the Fundamental Biology of Tregs to Fuel Treg Drug Development

9:30 am What is a Treg Cell? Defining Treg Cells to Clarify Function & Inform Therapeutic Development


  • Discussing the history of Treg cell characterization and where the space is headed
  • Providing a high-level overview of Treg role in autoimmunity, oncology and transplantation
  • Modulating Treg function to provide therapeutic impact

10:00 am Uncovering the Fundamental Biology of Regulatory T cells in Nonlymphoid Tissues


  • Understanding how Tregs differ depending on their location in the body
  • Outlining novel methods of functionally manipulating Tregs in different tissue compartments
  • Illuminating the factors that tissue-resident Tregs utilize for their maintenance and function

10:30 am
Morning Break & Refreshments

Divulging Mechanisms of Treg Instability to Optimize Stability of Treg Therapies

11:00 am Understanding the Cellular & Molecular Basis of IL-2-Dependent Regulatory T Cell Homeostasis during Treg-Directed Therapies


  • Benchmarking IL-2 as an essential survival signal for Treg homeostasis
  • Understanding the role of IL-2 in driving effector Treg cell development to balance activation
  • Delving into IL-2 dependent transcriptional and epigenetic regulation of Tregs to fuel further R&D

11:30 am Reprogramming of Regulatory T cells to Promote Immune Tolerance


  • Elucidating mechanisms of tolerance breakdown and Treg cells destabilization and degeneration
  • Elucidating Treg cell reprogramming in absence of Foxp3 to inform target selection
  • Providing examples of Treg cell destabilization and reprogramming in inflammatory and infectious diseases

12:00 pm
Lunch & Networking

Decoding Treg Subsets to Inform Selective Targeting & Fuel Biomarker Development

1:00 pm Elucidating the TCR Repertoire of Tregs to Inform Future Targeted Therapy Development


  • Decoding TCR of Tregs in health and diseases to inform low-dose IL2 in autoimmune disease
  • Exploring third-generation IL-2 muteins to form a disease-specific approach
  • Using IL-2 in and out to develop IL-2 self-sufficient Treg cells

1:30 pm Modulating a Newly Discovered Regulatory CD8 T cell Networking to Regulate & Eliminate Pathogenic CD4 T Cells in Autoimmune Disease


  • Understanding the seminal role that a novel CD8 Treg cell network plays in the inflammatory cascade and autoimmune-mediated gut disorders
  • Characterizing newly described CD8 Treg prevalence, phenotype and function, as well as their potential to modulate and reduce the severity of autoimmune disease
  • Discussing the therapeutic potential of bispecific Treg modulators to activate CD8 Tregs and eliminate pathogenic CD4 T cells to treat a host of human autoimmune disease

2:00 pm
Break & Networking

Deep-Diving Into Treg Dysregulation & Behaviour in Different Disease States to Supercharge Disease-Specific Drug Development

3:00 pm Understanding the role of Tregs in Inflammatory Conditions to Inform Autoimmune Strategy


  • Delving into the dysregulation of Tregs in the inflammatory environment and impact of improving functionality of Tregs under inflammatory conditions
  • Understanding the environments that lead to resistance of Tregs to find ways to enhance immune tolerance
  • Supporting Tregs in inflammatory conditions to inform drug development for autoimmunity, allergy, transplant

3:30 pm Elucidating Treg Dysregulation Due to IL-2 Deprivation in SLE & Other Rheumatic Diseases

  • Jens Humrich M.D. Consultant & Senior Clinician Scientist, Rheumatology, University Hospital Schleswig-Holstein


  • Understanding the pathophysiological relevance and characteristics of Treg dysregulation in rheumatic diseases
  • Dissecting the central role of acquired IL-2 deficiency in promoting Treg exhaustion and disease acceleration in SLE and other autoimmune diseases
  • Providing the clinical proof-of-concept for the use of low-dose IL-2 therapy aiming to restore Treg homeostasis in SLE

4:00 pm Selectively Depleting Tregs Using FOXP3 Antisense Oligonucleotides (ASO) to Improve Antitumor Immunity

  • Wayne William Hancock Professor of Pathology and Laboratory Medicine, Children’s Hospital of Philadelphia & University of Pennsylvania


  • Developing FOXP3 ASO to suppress Treg function in murine lung cancer models
  • Suppressing FOXP3 function in humanized mice to impair Treg function andprevent cancer growth
  • Eliciting unexpected actions and sustained effector T cell responses with knockdown of FOXP3

4:30 pm Chair’s Closing Remarks & End of Preconference Focus Day